Multiple choices for HIV therapy with integrase strand transfer inhibitors

Retrovirology

Volumn 9, Issue , 2012, Pages

  Raffi, Francois ^a   Wainberg, Mark A ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Dolutegravir; Elvitegravir; Integrase strand transfer inhibitors; Raltegravir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTEGRASE INHIBITOR; RALTEGRAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CREATININE CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVE SITE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRUS LOAD;

CLINICAL TRIALS AS TOPIC; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRROLIDINONES; QUINOLONES;

EID: 84871134805     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-110     Document Type: Article

References (15)

1. Malet I, Calvez V, Marcelin AG. The future of integrase inhibitors of HIV-1. Curr Opin Virol 2012, 2:580-587. 10.1016/j.coviro.2012.08.005, 22980926.
2. Koh Y, Matreyek KA, Engelman A. Differential sensitivities of retroviruses to integrase strand transfer inhibitors. J Virol 2011, 85:3677-3682. 10.1128/JVI.02541-10, 3067883, 21270168.
3. Mesplede T, Quashie PK, Wainberg MA. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS 2012, 7(5):401-408. 10.1097/COH.0b013e328356db89, 22789986.
4. Ni XJ, Delilis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF. G140S/Q148R and N155H mutations render HIV-2 integrase resistant to raltegravir whereas Y143C does not. Retrovirology 2011, 8:68. 10.1186/1742-4690-8-68, 3170264, 21854605.
5. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012, 379:2439-2448. 10.1016/S0140-6736(12)60917-9, 22748591.
6. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012, 379:2429-2438. 10.1016/S0140-6736(12)60918-0, 22748590.
7. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012, 12:27-35. 10.1016/S1473-3099(11)70249-3, 22015077.
8. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305:1327-1335. 10.1001/jama.2011.375, 3325645, 21467286.
9. Rockstroh J, DeJesus E, Saag M, Yazdanpanah Y, Lennox J, Wan H, Rodgers A, Dinubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P, . for the STARTMRK Study Team Long-term safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve HIV-1 infected patients: final 5-Yr double-blind results from STARTMRK 2012, Washington DC: Abstract LBPE19, IAC, for the STARTMRK Study Team.
10. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806. 10.1016/S0140-6736(09)60918-1, 19647866.
11. Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, Nguyen BY, Sklar P, Eron JJ, Wenning L. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 2012, 56:3101-3106. 10.1128/AAC.06417-11, 3370742, 22430964.
12. Eron JJ, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011, 11:907-915. 10.1016/S1473-3099(11)70196-7, 21933752.
13. Gras G, Schneider MP, Cavassini M, Lucht F, Loilier M, Verdon R, Bernard L, Parienti JJ. Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients: The RALTECAPS Cohort Study. J Acquir Immune Defic Syndr 2012, 61:265-269. 10.1097/QAI.0b013e31826cc592, 22895438.
14. Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results - SINGLE (ING114467). Abstract H-556b 2012, San Francisco, CA, USA, 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012.
15. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, , et al. et al, on behalf of the SPRING-2 study group Once-daily dolutegravirversus raltegravir in antiretroviral naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2012, accepted Oct 25, 2012, et al, on behalf of the SPRING-2 study group.